This phased funding opportunity supports early-stage translational research to develop and test medical device prototypes, identify disease targets, and develop assays and research tools for heart, lung, blood, and sleep diseases. The R61 phase focuses on initial prototype design and pilot testing, while the R33 phase supports continued development, user feedback integration, and large trial testing. The goal is to prepare products for in vivo testing and further development.
Eligible applicants include a wide range of U.S. organizations such as county and state governments, public and private higher education institutions, nonprofits, tribal organizations, small businesses, and for-profit organizations other than small businesses. Eligibility is limited to U.S.-based en
